Daily Archives: March 13, 2006

Does the Return of Tysabri Signal a New Direction?

On February 28th, 2005, Biogen Idec and Elan announced the market suspension of Tysabri, a treatment for multiple sclerosis.  The voluntary action was taken, per the Dear Healthcare Professional letter issued by the companies, out of reports that two patients … Continue reading

Posted in FDA Policy, Risk Management | Comments Off